Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The science of light and how ... more than 200 primary students in a traveling program ... of Otago Physics Department and funded by an ... of the university’s OSA/SPIE Student Chapter visited six primary ... children from small, rural schools hands-on lessons in optics ...
(Date:11/21/2014)... York, NY (PRWEB) November 20, 2014 ... is now available as an open access journal featuring ... with infrared fluorescent proteins to preserve photoresponsiveness in the ... Two-color fluorescent in situ hybridization using chromogenic substrates ... chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... 2014 Polaris Group announced today that ... Phase 1 trial of ADI-PEG 20 in combination ... malignant pleural mesothelioma (MPM) and non-squamous non-small cell ... on ADI-PEG 20, both as monotherapy and in ... several other indications, including breast cancer, melanomas, ovarian ...
(Date:11/18/2014)... RPS Diagnostics (RPS®) – a ... announces its third annual partnership of the Centers ... About Antibiotics Week from November 17-23. , Get ... designed to highlight the coordinated efforts of CDC, ... for-profit partners to provide education about the importance ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... Capability To Rapidly Identify Five Candida ... Blood Cultures In One Test, WOBURN, Mass., ... 510(k) clearance of the Yeast Traffic Light PNA ... blood cultures. The,Yeast Traffic Light(TM) is the latest ...
... at Rice University have discovered a novel method to ... are being studied in dozens of labs worldwide for ... viewscreens. , "The content of high-aspect-ratio gold nanorods produced ... percent," said lead researcher Eugene Zubarev, assistant professor of ...
... 22 For,his lifetime commitment in the field of ... exposures on the developing fetus and for,his leadership in ... PhD, will be honored as the recipient of the ... Health Care by Nemours,one of the nation,s largest children,s ...
Cached Biology Technology:AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3Purifying nanorods: Big success with tiny cleanup 2Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Children's Health Care 2
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
(Date:11/6/2014)... groundbreaking paper from a team of Florida State University ... plants could adapt to and survive environmental swings such ... the latest issue of the journal The Plant ... of DNA and proteins) is organized in a cell ... genes are turned on and others are turned off. ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2
... public divided about climate change because they don,t understand ... science and were more proficient in technical reasoning, would ... today online in the journal Nature Climate Change ... no. Indeed, as members of the public become more ...
... (RBC) is a critical component in the treatment ... problems. Indeed, approximately 75 million units of whole ... for processing and eventual transfusion. Despite this massive ... availability due to a combination of collection, manufacturing, ...
... the healthy growth of coral reefs in Hawaii may ... day treat human diseases, a new study led by ... Diego has revealed. An analysis led by Hyukjae ... Scripps, has shown that the seaweed, a tiny photosynthetic ...
Cached Biology News:Yale study concludes public apathy over climate change unrelated to science literacy 2Proteomic analysis of immunocamouflaged surfaces 2Nuisance seaweed found to produce compounds with biomedical potential 2
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... Monoclonal Anti-β-Tubulin IV Recognizes ... C-terminal sequence of β-tubulin isotype ... tubulin isotypes is observed. ascites ... the C-terminal sequence of β-tubulin ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Biology Products: